Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006–2013

Myint, Zin; Kunos, Charles

doi:10.3389/fonc.2020.01125

Cited by 6 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In PCa patients, the hypoestrogenic state induced by ADT leads to an increase in bone turnover and a 5-10-fold increase in the rate of areal BMD loss (9,10,39).…”

Section: Role Of Sex Hormones In Male Bone Remodeling and Adtinduced ...mentioning

confidence: 99%

“…In PCa patients, the hypoestrogenic state induced by ADT leads to an increase in bone turnover and a five- to ten-fold increase in the rate of areal BMD loss ( 9 , 10 , 39 ). As alternative to existing BSAs ( 13 ), bone health can be preserved and/or restored by the concomitant use of estrogens ( 21 , 25 ) or by estrogen monotherapy reaching castration levels of testosterone ( 20 ).…”

Section: Role Of Sex Hormones In Male Bone Remodeling and Adt-induced...mentioning

confidence: 99%

“…With improving survival rates of patients with advanced PCa, one of the major and serious consequences of ADT and the concomitant loss of E2 is increased bone turnover, causing bone loss, osteoporosis and fractures ( 9 , 10 , 11 ). Hip fractures are associated with higher all-cause mortality during and following ADT ( 12 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review

Bennink

Krijgh

Egberts³

et al. 2022

Endocrine Connections

View full text Add to dashboard Cite

The purpose of androgen deprivation therapy (ADT) in prostate cancer (PCa), using luteinizing hormone-releasing hormone agonists (LHRHa) or gonadotrophin releasing-hormone antagonists, is to suppress the levels of testosterone. Since testosterone is the precursor of estradiol (E2), one of the major undesired effects of ADT is the concomitant loss of E2, causing among others an increase in bone turnover and bone loss, and an increased risk of osteoporosis and fractures. Therefore, the guidelines for ADT indicate to combine ADT routinely with bone-sparing agents such as bisphophonates, denosumab or selective estrogen receptor modulators. However, these compounds may have side effects and some require inconvenient parenteral administration. (Co-)treatment with estrogens is an alternative approach to prevent bone loss, and at the same time avoid other side effects caused by the loss of estrogens, which is the topic explored in the present narrative review. Estrogens investigated in PCa patients include parenteral or transdermal E2, diethylstilbestrol (DES), and ethinylestradiol (EE) as monotherapy, or high-dose estetrol (HDE4) combined with ADT. Cardiovascular adverse events have been reported with parenteral E2, DES and EE. Encouraging effects on bone parameters have been obtained with transdermal E2 (tE2) and HDE4, in the tE2 development program (PATCH study), and in the LHRHa/HDE4 co-treatment study (PCombi), respectively. Confirmation of the beneficial effects of estrogen therapy with tE2 or HDE4 on bone health in patients with advanced PCa is needed, with special emphasis on bone mass and fracture rate.

show abstract

“…In PCa patients, the hypoestrogenic state induced by ADT leads to an increase in bone turnover and a 5-10-fold increase in the rate of areal BMD loss (9,10,39).…”

Section: Role Of Sex Hormones In Male Bone Remodeling and Adtinduced ...mentioning

confidence: 99%

Section: Role Of Sex Hormones In Male Bone Remodeling and Adt-induced...mentioning

confidence: 99%

See 1 more Smart Citation

Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review

Bennink

Krijgh

Egberts³

et al. 2022

Endocrine Connections

View full text Add to dashboard Cite

show abstract

“…[14,15] In addition, ADT may cause a variety of adverse effects, such as reduced stamina, increased fatigue, sexual dysfunction, fractures, cardiovascular disease and cognitive impairment, which often lead to poor drug tolerance. [2,[16][17][18][19][20] Moreover, PCa patients receiving broad-spectrum chemotherapy or other targeted therapies are prone to multidrug resistance, which accounts for more than 90% of deaths. [21,22] The existence of ADT and multidrug resistance has aroused a search for more alternatives to inhibit cancer cell proliferation and promote cancer cell death.…”

Section: Introductionmentioning

confidence: 99%

A review focusing on the role of pyroptosis in prostate cancer

Liu,

Kuang,

Chen

2023

Medicine

View full text Add to dashboard Cite

As one of the types of programmed cell death, pyroptosis has become a focus of research in recent years. Numerous studies have shown that pyroptosis plays a regulatory role in tumor cell invasiveness, differentiation, proliferation, and metastasis. It has been demonstrated that pyroptosis is involved in the regulation of signaling pathways implicated in the pathogenesis of prostate cancer (PCa). Furthermore, the loss of expression of pyroptosis-related genes in PCa has been reported, and pyroptosis-related genes have demonstrated a considerable ability in predicting the prognosis of PCa. Therefore, the potential role of pyroptosis in regulating the development of PCa warrants further investigation and attention. In this review, we summarize the basics of the role of pyroptosis and also discuss research into the mechanisms of action associated with pyroptosis in PCa. It is hoped that by exploring the potential of the pyroptosis pathway in intervening in PCa, it will provide a viable direction for the diversification of PCa treatment.

show abstract

Case Study #8: Alpha-Therapy with Radium-223 Dichloride for Metastatic Castration-Resistant Prostate Cancer

Pasquini,

Morris

2023

Radiopharmaceutical Therapy

View full text Add to dashboard Cite

Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006–2013

Cited by 6 publications

References 40 publications

Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review

Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review

A review focusing on the role of pyroptosis in prostate cancer

Case Study #8: Alpha-Therapy with Radium-223 Dichloride for Metastatic Castration-Resistant Prostate Cancer

Contact Info

Product

Resources

About